Pressemeddelelse
Zürich, 20.05.2008
A promising start into 2008
Very satisfactory first quarter, despite lower sales. Adjusted EBITDA increases due to lower costs. Most home markets performed very well. Major advancements in US out-licensing strategy. Bradley Pharmaceuticals integration largely finalised. Agreement with Zydus Cadila to shift API production to Indian joint venture.

Click here to read the entire press release at Nycomed.com.

Disclaimer